Special items: Ovarian Cancer and Us blog best viewed in Firefox

Thursday, March 04, 2010

Endocyte Announces DSMB Supports Continuation of Phase 2 PRECEDENT Study - EC145 combo

"The PRECEDENT study is a randomized phase 2 clinical trial comparing the company's drug EC145 in combination with pegylated liposomal doxorubicin (PLD/Doxil(R)) to PLD alone for women with platinum-resistant ovarian cancer."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.